CervoMed Inc.
$ 7.79
-1.39%
02 Jan - close price
- Market Cap 72,079,000 USD
- Current Price $ 7.79
- High / Low $ 8.00 / 7.60
- Stock P/E N/A
- Book Value 2.81
- EPS -2.90
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.43 %
- ROE -0.71 %
- 52 Week High 16.94
- 52 Week Low 1.92
About
CervoMed Inc. is a clinical-stage biotechnology firm based in Boston, dedicated to pioneering innovative therapeutics targeting neurodegenerative diseases, particularly Alzheimer's and Parkinson's. By employing advanced research methodologies and a robust drug pipeline, the company aims to meet critical unmet medical needs in these challenging therapeutic areas. CervoMed's commitment to innovation and strategic development positions it as a potential leader in transforming treatment paradigms, creating significant opportunities for enhanced patient outcomes and attractive returns for investors.
Analyst Target Price
$22.43
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-08 | 2025-06-13 | 2025-03-31 | 2024-11-11 | 2024-08-09 | 2024-05-14 | 2024-03-29 | 2023-11-13 | 2023-08-08 | 2023-05-15 | 2023-03-21 |
| Reported EPS | -0.84 | -0.7 | -0.56 | -0.8 | -0.5462 | -0.27 | -0.41 | -0.38 | -0.7 | -1.5537 | -2.01 | -2 |
| Estimated EPS | -0.46 | -0.68 | -0.6233 | -0.6343 | -0.41 | -0.31 | -0.39 | -0.29 | -0.95 | -2.9 | -1.91 | -2.22 |
| Surprise | -0.38 | -0.02 | 0.0633 | -0.1657 | -0.1362 | 0.04 | -0.02 | -0.09 | 0.25 | 1.3463 | -0.1 | 0.22 |
| Surprise Percentage | -82.6087% | -2.9412% | 10.1556% | -26.1233% | -33.2195% | 12.9032% | -5.1282% | -31.0345% | 26.3158% | 46.4241% | -5.2356% | 9.9099% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRVO
2026-01-01 17:08:29
CervoMed Inc. (NASDAQ:CRVO) has received a "Moderate Buy" consensus rating from eleven brokerages, with an average 12-month price target of $21.86, significantly higher than its current share price of around $7.90. Despite recent weak financial results, insider purchases, including by the CEO, indicate confidence, with insiders now owning 35.40% of the stock. Institutional investors hold 25.15%, while analysts have issued various ratings from "sell" to "strong buy."
2025-12-18 20:09:15
Cantor Fitzgerald has initiated coverage of CervoMed (NASDAQ:CRVO) with an Overweight rating, citing promising Phase 2 data for neflamapimod in dementia with Lewy bodies (DLB) and the drug's Fast Track Designation. Despite not yet being profitable, CervoMed maintains a strong liquidity position and is preparing for a Phase 3 registrational study in late 2026, with data expected in 2028. Recent positive feedback from the FDA on the Phase 3 trial design further supports the company's potential in a market currently lacking approved DLB therapies.
2025-12-18 20:09:10
Cantor Fitzgerald initiated an Overweight rating on CervoMed (NASDAQ:CRVO), citing promising Phase 2 data for neflamapimod in dementia with Lewy bodies (DLB) and its Fast Track Designation. The biotech company is undervalued with strong liquidity, and neflamapimod is expected to enter a Phase 3 study in 2026. This development comes as there are currently no approved therapies for DLB, offering significant potential for CervoMed's drug.
2025-12-18 19:09:27
HC Wainwright & Co. has reiterated a Buy rating for CervoMed (CRVO) with a $25.00 price target, aligning with consistent analyst support for the company. Other analysts, including Jason Kolbert of D. Boral Capital, have also maintained Buy ratings recently, with some price targets as high as $31.00. CervoMed, a clinical-stage biotechnology company, is focused on developing treatments for age-related neurologic disorders, with its product candidate Neflamapimod showing potential for conditions like DLB.
2025-12-18 13:09:23
HC Wainwright has reaffirmed a "Buy" rating for CervoMed (NASDAQ:CRVO) with a $25.00 price target, representing a potential upside of 212.9%. Despite missing Q3 earnings expectations and showing negative margins, institutional insider buying has been noted. Other analysts have varying ratings, though the consensus remains a "Moderate Buy" with an average target of $21.86.
2025-12-18 12:09:24
Cantor Fitzgerald has initiated coverage of CervoMed (NASDAQ:CRVO) with an Overweight rating, noting the company's promising Phase 2 data for neflamapimod in dementia with Lewy bodies (DLB). The small-cap biotech, with a market cap of $73.93 million, is preparing for a Phase 3 study of its neflamapimod drug, which has shown potential for disease-modifying activity. Despite not yet being profitable, CervoMed maintains a strong liquidity position and has received positive feedback from the FDA on its Phase 3 trial design.
